All In Biotech

Drug Trial Radar · NCT07018492

Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls

A Phase 1, Open-label, Parallel-group Study to Assess the Pharmacokinetics, Safety, and Tolerability of BPN14770 in Participants With Mild, Moderate, and Severe Hepatic Impairment and Healthy Control Participants

Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Aug 30, 2025

Primary completion

Nov 26, 2025

Study completion Nov 26, 2025

Sponsor

Lead sponsor
ShionogiIndustry
Sponsor type
Industry
First posted
Jun 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to assess the pharmacokinetics (PK) of BPN14770 after a single oral administration of BPN14770 in participants with mild, moderate, and severe liver impairment compared with control participants with normal hepatic function.

Conditions

  • Hepatic Impairment

Interventions

  • BPN14770Drug

    Administered as specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Plasma Concentration Time Curve Extrapolated from Time 0 to Infinity (AUCinf) of BPN14770Time frame: Predose up to 240 hours postdose
  2. Maximum Observed Plasma Concentration (Cmax) of BPN14770Time frame: Predose up to 240 hours postdose
  3. Time Maximum Observed Plasma Concentration (Tmax) of BPN14770Time frame: Predose up to 240 hours postdose

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Division of Clinical Pharmacology, University of Miami

    Miami, Florida

  • Orlando Clinical Research Center

    Orlando, Florida

  • Texas Liver Institute

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.